Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tectonic Therapeutic Inc (TECX)

Tectonic Therapeutic Inc (TECX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 573,074
  • Shares Outstanding, K 18,777
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,150 K
  • EBIT $ -84 M
  • EBITDA $ -83 M
  • 60-Month Beta 3.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.29

Options Overview Details

View History
  • Implied Volatility 102.79% (+1.92%)
  • Historical Volatility 94.05%
  • IV Percentile 26%
  • IV Rank 21.03%
  • IV High 213.83% on 10/07/25
  • IV Low 73.23% on 08/18/25
  • Expected Move (DTE 13) 4.85 (15.87%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 166
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 5,637
  • Open Int (30-Day) 5,212
  • Expected Range 25.68 to 35.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.14
  • Number of Estimates 5
  • High Estimate $-1.05
  • Low Estimate $-1.26
  • Prior Year $-0.93
  • Growth Rate Est. (year over year) -22.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.70 +40.65%
on 03/03/26
36.03 -15.29%
on 03/06/26
+7.52 (+32.70%)
since 03/02/26
3-Month
16.77 +81.99%
on 02/10/26
36.03 -15.29%
on 03/06/26
+9.61 (+45.96%)
since 01/02/26
52-Week
13.70 +122.77%
on 04/09/25
36.03 -15.29%
on 03/06/26
+12.63 (+70.60%)
since 04/02/25

Most Recent Stories

More News
Tectonic Therapeutic to Participate in March Investor Conferences

WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic , Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic...

TECX : 30.52 (-0.84%)
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) in...

TECX : 30.52 (-0.84%)
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc.  (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic...

TECX : 30.52 (-0.84%)
MRNA : 49.20 (-1.66%)
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc . (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic...

TECX : 30.52 (-0.84%)
Tectonic Therapeutic to Participate in December Investor Conferences

WATERTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic , Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic...

TECX : 30.52 (-0.84%)
Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights

Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure...

TECX : 30.52 (-0.84%)
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF

TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”) TX45 was well tolerated...

TECX : 30.52 (-0.84%)
Mizuho Securities Keeps Their Buy Rating on Tectonic Therapeutic (TECX)

In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Tectonic Therapeutic, with a price target of $85.00. The company’s shares closed today at $16.09.Elevate Your Investing...

TECX : 30.52 (-0.84%)
Tectonic Therapeutic to Participate in September Investor Conferences

WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic , Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic...

TECX : 30.52 (-0.84%)
Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights

TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease (“PH-ILD”,...

TECX : 30.52 (-0.84%)

Business Summary

Tectonic Therapeutic Inc. is a biotechnology company developing GPCR -targeted therapeutic proteins. Tectonic Therapeutic Inc., formerly known as AVROBIO Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 33.28
2nd Resistance Point 32.54
1st Resistance Point 31.53
Last Price 30.52
1st Support Level 29.78
2nd Support Level 29.04
3rd Support Level 28.03

See More

52-Week High 36.03
Last Price 30.52
Fibonacci 61.8% 27.50
Fibonacci 50% 24.86
Fibonacci 38.2% 22.23
52-Week Low 13.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.